Perspectives on lymphangiogenesis and angiogenesis in cancer

Authors

  • Tanja Holopainen MD,

  • Maija Bry BMed,

    1. Molecular/Cancer Biology Laboratory, Research Program Unit, Department of Pathology, Haartman Institute, Institute for Molecular Medicine Finland, Helsinki University Central Hospital, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    Search for more papers by this author
  • Kari Alitalo MD, PhD,

    1. Molecular/Cancer Biology Laboratory, Research Program Unit, Department of Pathology, Haartman Institute, Institute for Molecular Medicine Finland, Helsinki University Central Hospital, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    Search for more papers by this author
  • Anne Saaristo MD, PhD

    Corresponding author
    1. Molecular/Cancer Biology Laboratory, Research Program Unit, Department of Pathology, Haartman Institute, Institute for Molecular Medicine Finland, Helsinki University Central Hospital, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    2. Plastic Surgery, Turku University Central Hospital, Finland
    • Molecular/Cancer Biology Laboratory, Biomedicum Helsinki, P.O. Box 63 (Haartmaninkatu 8), University of Helsinki, Helsinki 00014, Finland. Fax No.: 358-9-1912 5510.
    Search for more papers by this author

  • Conflict of interest: K.A. is chairman of SAB, Circadian Ltd., shareholder in Ark Therapeutics Ltd. (<8000 €), and the principal investigator of a research grant from LX Therapies. Dr Anne Saaristo is member of the board of directors of OY Lx Therapies Ltd.

Abstract

Tumor-associated neovascularization allows tumor cells to express their critical growth advantage, whereas lymphatic invasion is crucial for the metastatic process. Various growth factors stimulate blood and lymphatic neovascularization and modulate vessel permeability in tumors. The first anti-angiogenic drugs are already in routine use, and new anti-vascular therapeutics are evaluated in clinical trials. Conversely, pro-lymphangiogenic therapy could be implemented to treat cancer survivors suffering from secondary lymphedema. J. Surg. Oncol. 2011;103:484–488. © 2011 Wiley-Liss, Inc.

Ancillary